Objective: To examine the cost-effectiveness of a newly approved combination of bempedoic acid and ezetimibe (BAEze) in patients with ASCVD from a U.S. healthcare sector perspective. Methods: State-transition Markov model of US adults with ASCVD and low-density lipoprotein cholesterol (LDL-C) ...
From a practical standpoint, this review is exclusively concerned with the currently available lipid-lowering agents: statins, ezetimibe, anti-PCSK9 monoclonal antibodies, the small interfering RNA (siRNA) agent inclisiran, and bempedoic acid. Lipid-lowering treatment protocols are changing, including ...
725 Cost Effectiveness of Bempedoic Acid for Those at High Risk Cardiovascular Diseasedoi:10.1016/j.hlc.2020.09.732K. PereraN. KamZ. AdemiD. LiewE. ZomerHeart, Lung and Circulation
Bempedoic acidCost-effectivenessCardiovascular diseaseLipid-loweringPreventionBACKGROUND: Bempedoic acid is a novel adenosine triphosphate citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol when used as an adjunct lipid-lowering therapy in patients with high cardiovascular disease (CVD)...